Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.
Eli Lilly projects 32% revenue growth for 2025, fueled by incretin expansion and new launches
Q4 2024 Management View CEO David Ricks highlighted a 45% revenue growth in Q4, with significant contributions from Mounjaro and Zepbound. He emphasized ongoing expansion in manufacturing to meet ...
Eli Lilly and Company (NYSE:LLY) Trading 0.1% Higher After Analyst Upgrade
Eli Lilly and Company (NYSE:LLY – Get Free Report)’s stock price rose 0.1% on Tuesday after Truist Financial raised their price target on the stock from $1,029.00 to $1,038.00. Truist Financial ...
Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Eli Lilly and Company (NYSE:LLY) Shares Up 0.1% on Analyst Upgrade
Eli Lilly and Company (NYSE:LLY – Get Free Report) traded up 0.1% during mid-day trading on Monday after Truist Financial raised their price target on the stock from $1,029.00 to $1,038.00. Truist ...
Jim Cramer on Eli Lilly and Company (LLY): ‘It’s About The Scripts, Not About The Pill’
In a fresh appearance on CNBC’s Squawk on the Street, Jim Cramer cautioned viewers to not be caught up by the energy that’s ...
Seeking Alpha8d
LLY Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...